Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2013 1
2016 1
2017 2
2018 3
2019 3
2020 5
2021 6
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean cheung wan chee (2 results)?
Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines.
Bonney GK, Chew CA, Lodge P, Hubbard J, Halazun KJ, Trunecka P, Muiesan P, Mirza DF, Isaac J, Laing RW, Iyer SG, Chee CE, Yong WP, Muthiah MD, Panaro F, Sanabria J, Grothey A, Moodley K, Chau I, Chan ACY, Wang CC, Menon K, Sapisochin G, Hagness M, Dueland S, Line PD, Adam R. Bonney GK, et al. Among authors: chee ce. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):933-946. doi: 10.1016/S2468-1253(21)00219-3. Epub 2021 Sep 8. Lancet Gastroenterol Hepatol. 2021. PMID: 34506756
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Bendell JC, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Lockhart AC, Knutson KL, Yen J, Franovic A, Nordstrom JL, Li D, Wigginton J, Davidson-Moncada JK, Rosales MK, Bang YJ; CP-MGAH22-5 Study Group. Catenacci DVT, et al. Among authors: chee ce. Lancet Oncol. 2020 Aug;21(8):1066-1076. doi: 10.1016/S1470-2045(20)30326-0. Epub 2020 Jul 9. Lancet Oncol. 2020. PMID: 32653053 Clinical Trial.
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn PZ, He P, McDevitt J, Sheth S, Englert JM, Ku GY. Kelly RJ, et al. Among authors: chee ce. Clin Cancer Res. 2020 Feb 15;26(4):846-854. doi: 10.1158/1078-0432.CCR-19-2443. Epub 2019 Nov 1. Clin Cancer Res. 2020. PMID: 31676670 Free PMC article. Clinical Trial.
Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.
Zhao Y, Shuen TWH, Toh TB, Chan XY, Liu M, Tan SY, Fan Y, Yang H, Lyer SG, Bonney GK, Loh E, Chang KTE, Tan TC, Zhai W, Chan JKY, Chow EK, Chee CE, Lee GH, Dan YY, Chow PK, Toh HC, Lim SG, Chen Q. Zhao Y, et al. Among authors: chee ce. Gut. 2018 Oct;67(10):1845-1854. doi: 10.1136/gutjnl-2017-315201. Epub 2018 Mar 30. Gut. 2018. PMID: 29602780 Free PMC article.
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q. Thura M, et al. Among authors: chee ce. Nat Commun. 2021 Nov 2;12(1):6431. doi: 10.1038/s41467-021-26548-6. Nat Commun. 2021. PMID: 34728638 Free PMC article. No abstract available.
Statistical Process Control Charts for Monitoring Next-Generation Sequencing and Bioinformatics Turnaround in Precision Medicine Initiatives.
Jain SR, Sim W, Ng CH, Chin YH, Lim WH, Syn NL, Kamal NHBA, Gupta M, Heong V, Lee XW, Sapari NS, Koh XQ, Isa ZFA, Ho L, O'Hara C, Ulagapan A, Gu SY, Shroff K, Weng RC, Lim JSY, Lim D, Pang B, Ng LK, Wong A, Soo RA, Yong WP, Chee CE, Lee SC, Goh BC, Soong R, Tan DSP. Jain SR, et al. Among authors: chee ce. Front Oncol. 2021 Sep 24;11:736265. doi: 10.3389/fonc.2021.736265. eCollection 2021. Front Oncol. 2021. PMID: 34631570 Free PMC article.
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M, Al-Aidaroos AQ, Gupta A, Chee CE, Lee SC, Hui KM, Li J, Guan YK, Yong WP, So J, Chng WJ, Ng CH, Zhou J, Wang LZ, Yuen JSP, Ho HSS, Yi SM, Chiong E, Choo SP, Ngeow J, Ng MCH, Chua C, Yeo ESA, Tan IBH, Sng JXE, Tan NYZ, Thiery JP, Goh BC, Zeng Q. Thura M, et al. Among authors: chee ce. Nat Commun. 2019 Jun 6;10(1):2484. doi: 10.1038/s41467-019-10127-x. Nat Commun. 2019. PMID: 31171773 Free PMC article.
21 results